Segall Bryant & Hamill LLC Buys New Stake in OptimizeRx Corp. $OPRX

Segall Bryant & Hamill LLC acquired a new position in OptimizeRx Corp. (NASDAQ:OPRX) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 188,704 shares of the company’s stock, valued at approximately $1,185,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Hillsdale Investment Management Inc. grew its stake in OptimizeRx by 10.9% in the 4th quarter. Hillsdale Investment Management Inc. now owns 20,300 shares of the company’s stock valued at $249,000 after acquiring an additional 2,000 shares during the period. Parkman Healthcare Partners LLC lifted its holdings in OptimizeRx by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock valued at $10,447,000 after purchasing an additional 2,188 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the period. AQR Capital Management LLC boosted its holdings in OptimizeRx by 18.4% in the 4th quarter. AQR Capital Management LLC now owns 14,514 shares of the company’s stock worth $178,000 after buying an additional 2,256 shares during the last quarter. Finally, Harbor Capital Advisors Inc. boosted its stake in shares of OptimizeRx by 12.2% in the fourth quarter. Harbor Capital Advisors Inc. now owns 24,876 shares of the company’s stock worth $305,000 after acquiring an additional 2,708 shares during the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on OPRX. UBS Group set a $10.00 price target on shares of OptimizeRx in a research note on Wednesday, May 13th. Weiss Ratings downgraded shares of OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, May 14th. Lake Street Capital decreased their price target on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Stifel Nicolaus lowered their price objective on shares of OptimizeRx from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Finally, B. Riley Financial dropped their price objective on shares of OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $13.43.

OptimizeRx Stock Performance

NASDAQ OPRX opened at $6.93 on Thursday. The stock has a market capitalization of $130.04 million, a price-to-earnings ratio of 19.80 and a beta of 1.08. The business’s 50 day moving average is $5.79 and its two-hundred day moving average is $6.92. OptimizeRx Corp. has a 12-month low of $4.54 and a 12-month high of $22.25. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.16.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Tuesday, May 12th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $19.84 million during the quarter, compared to the consensus estimate of $18.74 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%. Research analysts expect that OptimizeRx Corp. will post 0.51 EPS for the current year.

OptimizeRx Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.